"He said that the administration has "some great people working on this project," but he would "give the program, and what we know, as of today, a grade of B." "Why not an A? The stock prices of PBMs didn't get crushed," wrote Cuban. "Which means, so far, no one expects much change for them. Which they expect they will make up lost revenues from patients, companies, and other payers elsewhere.""
""It's still rigged to benefit the big PBMs," Cuban added in response to a post asking if Trump's operation could run honestly without favor. "That said, it has a chance if they force PBMs to change. If that happens, Trump gets all the credit and it will be deserved.""
"In an email to Business Insider, Cuban said of TrumpRx.gov, "it's just a listing site.. And as long as they include Cost Plus Drugs, given we typically have the lowest prices for more than 90% of prescriptions, I'm all for it!""
Trump plans to launch TrumpRx.gov to let consumers buy prescription drugs directly from manufacturers without Pharmacy Benefit Managers as intermediaries, with the administration targeting a 2026 release. Mark Cuban said the approach could benefit patients and might boost his Cost Plus Drugs business, and he praised the people working on the project while assigning it a grade of B. Cuban noted PBM stock prices did not fall, signaling little expected disruption, and warned the system remains tilted toward large PBMs. He said the initiative could succeed only if PBMs are forced to change and urged inclusion of Cost Plus Drugs on the site.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]